Clinique Victor Hugo - Centre Jean Bernard

Le Mans, Sarthe 72015

0 studies enrolling now · 7 studies all time

What they study most

Breast Cancer, Clear-cell Metastatic Renal Cell Carcinoma, First Line Non-Small Cell Lung Cancer, Lymphoma, Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Studies at this site

• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] — Completed
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) — Completed
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer — Completed
• Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) — Completed
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma — Completed